Fujifilm Diosynth Biotechnologies
Corporate brand
UnclaimedLeading global contract development and manufacturing organization (CDMO) for biopharmaceuticals.
Last updated November 4, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Fujifilm Diosynth Biotechnologies is a contract development and manufacturing organization (CDMO) under the Fujifilm Group, providing development and manufacturing services for biologics to global clients. The company has facilities in the UK, US, and Denmark.
Products and positioning
A leading global biopharmaceutical CDMO
Recent events
- Unconfirmed
Reported
Fujifilm selects North Carolina site for planned manufacturing facility[1]
Fujifilm Diosynth Biotechnologies chose Holly Springs, North Carolina, as the site for its planned $2 billion cell-culture manufacturing facility. The company said the facility would add just under 1,000 jobs in the area by 2028.
Fujifilm Diosynth announces North Carolina manufacturing facility plan[2]
Fujifilm Diosynth Biotechnologies announced plans to build a drug manufacturing facility in Holly Springs, North Carolina, with a planned $2 billion investment and 725 jobs.
Fujifilm Diosynth announces planned North Carolina drug manufacturing facility[3]
Fujifilm Diosynth Biotechnologies announced plans to build a drug manufacturing facility in Holly Springs, North Carolina, with a stated investment of $2 billion and 725 jobs.
Reported
FUJIFILM Diosynth Biotechnologies announces CEO succession[4]
FUJIFILM Diosynth Biotechnologies announced that Martin Meeson had been appointed to succeed Steve Bagshaw as CEO. Bagshaw's retirement from the CEO position and Meeson's succession were stated to take effect on April 1, 2020; Bagshaw would continue as non-executive chairman.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/fujifilm-diosynth-biotechnologies · Editorial policy · How profiles are compiled